Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Entyvio | Vedolizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jardiance | Empagliflozin | Diabetes mellitus, type 2 with high cardiovascular risk | Reimburse with clinical criteria and/or conditions | Complete | ||
| Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Viacoram | perindopril arginine / amlodipine | Hypertension, essential | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lixiana NVAF | Edoxaban | Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lixiana VTE | Edoxaban | Venous thromboembolism, treatment and recurrence prevention. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ibrance Resubmission | Palbociclib | Advanced breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Afinitor | Everolimus | Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin | Reimburse with clinical criteria and/or conditions | Complete | ||
| Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 9, 2024